Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...

Insights on the Ankylosing Spondylitis Global Market to 2030 - Rise in Number of Hospitals and Diagnostic Centers is Driving Growth Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Market by Drug Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been...

Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).Sofusa is a revolutionary technology which delivers biologic...

Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the...